ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2125

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

mohammad hammad saied1, Liora Harel 2, Gil Amarilyo 3, rotem tal 4 and Razi Zidani 5, 1schneider medical center, kaboul village, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3schneider medical center, petach tekva, 4schneider medical center, ramat gan, Israel, 5tel aviv university, Tamra, Israel

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Infection, pediatric rheumatology and fever

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Infection-Related Rheumatic Disease Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of the disease, and valvular impairment, leading to a significant hemodynamic disturbance, as a late sequela.

Aim

To examine the number of cases of Rheumatic fever in Schneider Children’s medical center, and to find whether it has declined during the years of its existence. In addition, to characterize the patient population, clinical characteristics, risk factors and asses the course of the disease. In addition, we will address the relapse rates, with an emphasis on cardiac relapses, with a correlation to preventive treatment.

Methods: Retrospective cohort study was conducted, collecting data of patients with rheumatic fever who were admitted to the Schneider Medical Center from 1993 to 2017.

Results: 307 patients met the inclusion criteria. During the acute phase,64% presented with arthritis, 52%  carditis,  15% chorea, 5% erythema marginatum, and 0.7% with subcutaneous nodules. 19.5% developed severe carditis, 13% of whom developed heart failure signs. There was a decrease in incidence of rheumatic fever and rheumatic heart disease during the study period. Median follow-up time was 49 months, 12% of all patients developed a relapse of the disease and 11 of whom (4% of all patients) developed a cardiac relapse.
15% of the patients who received oral prophylaxis experienced relapse, compared to 9% of those who received intramuscular injection therapy.

Conclusion: Despite the reduction in incidence of rheumatic fever and rheumatic heart disease during the study period, the disease remains a significant cause of general and cardiac morbidity among children despite being completely preventable, therefore, It should remain in the mind of every doctor, pediatricians in particular.


Incidence

Rheumatic Fever and Carditis Incidence Proportion of Overall Hospitalized Patients in Schneider for that year


recurrnce

Rheumatic Fever – Overall Recurrence Rate


joints

Joint Involvement


Disclosure: m. hammad saied, None; L. Harel, None; G. Amarilyo, None; r. tal, None; R. Zidani, None.

To cite this abstract in AMA style:

hammad saied m, Harel L, Amarilyo G, tal r, Zidani R. Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/rheumatic-fever-in-a-tertiary-medical-center-25-years-of-follow-up/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatic-fever-in-a-tertiary-medical-center-25-years-of-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology